|LETTER TO EDITOR
|Year : 2020 | Volume
| Issue : 4 | Page : 856
Authors' reply to Divya et al.
Supriya Adak, Gunjesh Kumar Singh, Nandini Menon, Vijay Patil
Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India
|Date of Submission||20-Nov-2020|
|Date of Decision||24-Nov-2020|
|Date of Acceptance||04-Dec-2020|
|Date of Web Publication||25-Dec-2020|
Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Adak S, Singh GK, Menon N, Patil V. Authors' reply to Divya et al. Cancer Res Stat Treat 2020;3:856
We would like to thank Divya et al. for their valuable comments on our article on cognitive scores in patients with primary brain tumors undergoing systemic therapy published in the previous issue of the journal. We would also like to thank Dutta and Jalali for their encouragement and interest in our study.
In central nervous system malignancies, the origin and cause of cognitive impairment are complicated aspects interlinked to a plethora of parameters that rightly demand an in-depth exploration. Studying the effects of systemic therapy alone in patients with brain tumors is considerably difficult because most patients with primary brain tumors receive chemotherapy following surgery or radiotherapy.
Studies on treatment-related cognitive deficits post surgery and radiotherapy have shown that both the treatment modalities contribute fairly to the long-term adverse effects on cognition.
We agree with Divya et al. that incorporating variables such as cognitive reserve, baseline cognitive level, genetic predisposition, and comorbidities would likely increase the possibility of finding an association between chemotherapeutic agents and cognitive impairment.
As mentioned in our original article, a large prospective longitudinal study would justifiably compare the cognitive levels in patients both before and after the treatment as well as record the changes.
Furthermore, comparison between the current scores derived from our study with the scores of a control group (patients who did not receive systemic therapy) is a substantial recommendation, and we would definitely like to build on the idea in future.
The authors would like to thank Neuro-Oncology DMG, Tata Memorial Hospital, Parel.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Divya KP, Cherian A, Anoop TM. Systemic chemotherapy and cognitive dysfunction in primary brain tumors - To incriminate or exculpate? Cancer Res Stat? Treat 2020;3:854-5.
Adak S, Singh GK, Menon N, Dale O, Srinivas S, Das S, et al
. Cognitive score in patients with primary brain tumors undergoing systemic therapy – A cross-sectional study. Cancer Res Stat Treat 2020;3:455-60. [Full text]
Dutta D, Jalali R. Impact of systemic therapies on cognition in patients with primary brain tumors. Cancer Res Stat Treat 2020;3:569-71. [Full text]
Talacchi A, Santini B, Savazzi S, Gerosa M. Cognitive effects of tumour and surgical treatment in glioma patients. J Neurooncol 2011;103:541-9.
Makale MT, McDonald CR, Hattangadi-Gluth JA, Kesari S. Mechanisms of radiotherapy-associated cognitive disability in patients with brain tumours. Nat Rev Neurol 2017;13:52-64.